From In Vitro Cytotoxicity to In Vivo Zebrafish Assays: A Study on 3,3-Dichloro β-, γ- and δ-Lactams and Their Biological Activity Profiles
<b>Background/Objectives:</b> Anticancer research is a constantly evolving field due to cancer's complexity and adaptability. This study aims to evaluate the hemolytic behavior and cytotoxic properties of ten 3,3-dichlorolactams against A431 tumor and 3T3 fibroblast cells, with a particular focus on their selective toxicity. <b>Methods:</b> To achieve this, we assessed the hemocompatibility and cytotoxic effects of the lactams, determining their impact on cell viability through MTT and NRU assays. Additionally, AO/EtBr double staining was used to confirm apoptosis as a mechanism of cell death. To complement the in vitro findings, in vivo experiments were conducted using Zebrafish embryos to evaluate acute, developmental, and neurotoxic effects. <b>Results:</b> The results demonstrated that all lactams were hemocompatible, with the cytotoxicity influenced mainly by their structure and the tested concentration. β-Lactam 1 was the most efficient in inducing selective toxicity against A431 cells, showing the lowest IC<sub>50</sub> values (71 μg/mL and 210 μg/mL (MTT) and 35 μg/mL and >250 μg/mL (NRU) for A431 and 3T3 cell lines, respectively), with SI values close to 3 and >7. Moreover, cell death induction through apoptosis was confirmed by AO/EtBr double staining. Finally, despite its lower acute toxicity compared to other anticancer agents, the in vivo experiments revealed that <b>1</b> induced developmental toxicity and neurotoxic effects in Zebrafish embryos at concentrations lower than those affecting A431 cancer cells. <b>Conclusions:</b> the study highlights the potential of β-lactam derivatives as promising anticancer agents while emphasizing the need for comprehensive safety assessments. Future research should further explore structural modifications to enhance efficacy and specificity while minimizing adverse effects.
Authors
- M. Carmen Morán (ORCID: https://orcid.org/0000-0003-2336-9540)
- Elisabet Teixidó (ORCID: https://orcid.org/0000-0002-0146-876X)
- Fai͏̈za Diaba (ORCID: https://orcid.org/0000-0001-9950-2470)
Institutions
- Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2025-03-28
- DOI
- https://doi.org/10.3390/ph18040488
- Citations
- 1
- Primary Topic
- Synthesis of β-Lactam Compounds
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Fundació Bosch i Gimpera